Cabotegravir; Rilpivirine Patent Expiration
Cabotegravir; Rilpivirine is Used for treating HIV-1 infection in adults and adolescents aged 12 years and older. It was first introduced by Viiv Healthcare Co
Cabotegravir; Rilpivirine Patents
Given below is the list of patents protecting Cabotegravir; Rilpivirine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cabenuva Kit | US10927129 | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity | Apr 28, 2026 | Viiv Hlthcare |
| Cabenuva Kit | US11224597 | Pharmaceutical compositions | Sep 15, 2031 | Viiv Hlthcare |
| Cabenuva Kit | US11389447 | Aqueous suspensions of TMC278 | Jun 30, 2027 | Viiv Hlthcare |
| Cabenuva Kit | US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb 26, 2021
(Expired) | Viiv Hlthcare |
| Cabenuva Kit | US7125879 | HIV inhibiting pyrimidines derivatives | Apr 21, 2025 | Viiv Hlthcare |
| Cabenuva Kit | US8080551 | HIV inhibiting pyrimidines derivatives |
Apr 11, 2023
(Expired) | Viiv Hlthcare |
| Cabenuva Kit | US8410103 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent | Apr 28, 2026 | Viiv Hlthcare |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳